ATE550658T1 - Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden - Google Patents

Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden

Info

Publication number
ATE550658T1
ATE550658T1 AT07749017T AT07749017T ATE550658T1 AT E550658 T1 ATE550658 T1 AT E550658T1 AT 07749017 T AT07749017 T AT 07749017T AT 07749017 T AT07749017 T AT 07749017T AT E550658 T1 ATE550658 T1 AT E550658T1
Authority
AT
Austria
Prior art keywords
sample
autoantibody
level
subject
condition
Prior art date
Application number
AT07749017T
Other languages
English (en)
Inventor
John A Mcintyre
Original Assignee
John A Mcintyre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John A Mcintyre filed Critical John A Mcintyre
Application granted granted Critical
Publication of ATE550658T1 publication Critical patent/ATE550658T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT07749017T 2006-02-23 2007-01-22 Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden ATE550658T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/359,489 US7892751B2 (en) 2003-06-09 2006-02-23 Method of detecting or diagnosing of a neurodegenerative disease or condition
PCT/US2007/001582 WO2007106224A2 (en) 2006-02-23 2007-01-22 Method of detecting or diagnosing of a neurodegenerative disease or condition

Publications (1)

Publication Number Publication Date
ATE550658T1 true ATE550658T1 (de) 2012-04-15

Family

ID=38509957

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07749017T ATE550658T1 (de) 2006-02-23 2007-01-22 Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden

Country Status (9)

Country Link
US (1) US7892751B2 (de)
EP (1) EP1989551B1 (de)
JP (1) JP4880001B2 (de)
AT (1) ATE550658T1 (de)
AU (1) AU2007225434B2 (de)
BR (1) BRPI0708138A2 (de)
CA (1) CA2642869C (de)
MX (1) MX2008010896A (de)
WO (1) WO2007106224A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CA2730042A1 (en) * 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for alzheimer's disease
CA2736189A1 (en) * 2008-09-04 2010-03-11 Redox-Reactive Reagents, Llc Biomarkers, kits, and method for diagnosing, monitoring, and/or staging alzheimer's disease
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120107841A1 (en) * 2010-07-19 2012-05-03 Mcintyre John A Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
ES2748117T3 (es) * 2015-04-22 2020-03-13 Euroimmun Medizinische Labordiagnostika Ag Diagnóstico de una nueva enfermedad autoinmune
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703001A (en) 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4950612A (en) 1987-12-16 1990-08-21 Microgenics Corporation Peroxy acid pretreatment in vitamin B12 assay
US5061790A (en) 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
AU703814B2 (en) 1995-12-04 1999-04-01 Wyeth Antioxidant
US5939394A (en) 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR2822238B1 (fr) 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
US9557325B2 (en) 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
AU2004248155B2 (en) 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Also Published As

Publication number Publication date
WO2007106224A2 (en) 2007-09-20
EP1989551B1 (de) 2012-03-21
JP2009527762A (ja) 2009-07-30
EP1989551A4 (de) 2010-01-06
CA2642869A1 (en) 2007-09-20
CA2642869C (en) 2017-04-11
EP1989551A2 (de) 2008-11-12
AU2007225434A8 (en) 2011-05-12
BRPI0708138A2 (pt) 2011-05-17
WO2007106224B1 (en) 2008-03-20
AU2007225434B2 (en) 2011-05-26
JP4880001B2 (ja) 2012-02-22
WO2007106224A3 (en) 2008-01-31
AU2007225434A1 (en) 2007-09-20
MX2008010896A (es) 2008-11-25
US7892751B2 (en) 2011-02-22
US20060141541A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
ATE550658T1 (de) Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010057184A3 (en) Methods for detection of acute kidney injury in humans
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ601575A (en) Methods and compositions for diagnosis and prognosis of renal injury and failure
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ604873A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CO6741144A2 (es) Indicador vaginal para detectar biomarcadores de una buena salud
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
GB2467704A (en) Methods of monitoring conditions by sequence analysis
EA200970758A1 (ru) Диагностика и лечение преэклампсии
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
NZ700695A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE518139T1 (de) Verfahren zur diagnose einer krankheit mit beteiligung eines anti-at1-rezeptor-antikörpers
EP4465051A3 (de) Biomarker und verfahren zur beurteilung und behandlung von epileptischen vs nichtepileptischen anfällen / keine anfälle / psychogene nichtepileptische anfälle
NZ592819A (en) Thyroid analyte detection and measurement
NZ612673A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure
Duriseti et al. Cost-effectiveness of strategies for diagnosing pulmonary embolism among emergency department patients presenting with undifferentiated symptoms
JP2006311860A5 (de)
RU2008103988A (ru) Способ диагностики рассеяного склероза